| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2249.1993.TB03407.X |
| P953 | full work available at URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2249.1993.tb03407.x |
| https://academic.oup.com/cei/article-pdf/92/3/369/42211932/j.1365-2249.1993.tb03407.x.pdf | ||
| https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2249.1993.tb03407.x | ||
| P932 | PMC publication ID | 1554769 |
| P698 | PubMed publication ID | 7685668 |
| P5875 | ResearchGate publication ID | 15512833 |
| P2093 | author name string | M. D. Kazatchkine | |
| L. Boumsell | |||
| C. Gelin | |||
| S. V. Kaveri | |||
| T. Vassilev | |||
| M. T. Zilber | |||
| P2860 | cites work | Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production | Q46683088 |
| Rheumatoid factor secretion from human Leu-1+ B cells. | Q52256894 | ||
| Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice | Q59055762 | ||
| Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies | Q63859676 | ||
| Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain | Q67538882 | ||
| B cells expressing CD5 are increased in Sjögren's syndrome | Q68094459 | ||
| Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg) | Q68126476 | ||
| Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies | Q68551228 | ||
| Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset | Q70333975 | ||
| Genetic influence on the levels of circulating CD5 B lymphocytes | Q70349938 | ||
| Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates | Q70534822 | ||
| Expression and control of the natural autoreactive IgG repertoire in normal human serum | Q70623815 | ||
| Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibo | Q72651281 | ||
| Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain | Q30195408 | ||
| Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura | Q33476148 | ||
| Use of intravenous immunoglobulin in chronic lymphocytic leukemia | Q33478219 | ||
| Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin | Q33481729 | ||
| Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus | Q34240804 | ||
| A transgenic model of autoimmune hemolytic anemia | Q36230807 | ||
| An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells | Q36343834 | ||
| Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis | Q36355678 | ||
| Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’ | Q36676057 | ||
| Manipulating the Immune System with Immune Globulin | Q36725772 | ||
| Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network | Q36731959 | ||
| Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits | Q37016993 | ||
| Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases | Q37433060 | ||
| The CD5 B cell | Q38208984 | ||
| Natural mouse IgG reacts with self antigens including molecules involved in the immune response | Q44321821 | ||
| Auto- and polyreactivity of IgM from CD5+ and CD5- cord blood B cells | Q44950652 | ||
| A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. | Q45210042 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 369-372 | |
| P577 | publication date | 1993-06-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) | |
| P478 | volume | 92 |
| Q33501707 | Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice |
| Q37351865 | Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. |
| Q37773433 | Antibody-mediated modulation of immune responses. |
| Q33817905 | Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity |
| Q36602762 | Basic principles of intravenous immunoglobulin (IVIg) treatment |
| Q33364381 | Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? |
| Q36264883 | Clinical uses of intravenous immunoglobulin. |
| Q34620111 | Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies |
| Q43025032 | Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. |
| Q31949259 | Genetic origin of IgG antibodies cloned by phage display and anti-idiotypic panning from three patients with autoimmune thrombocytopenia |
| Q35146924 | Immunobiologic consequences of assist devices |
| Q39808657 | Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. |
| Q33596381 | Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases |
| Q41589704 | Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies? |
| Q35013334 | Immunomodulatory action of intravenous immunoglobulin. |
| Q41663188 | In vitro effects of polyvalent immunoglobulin for intravenous use. |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q35160125 | Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications |
| Q35542385 | Intravenous immune globulins: an update for clinicians |
| Q36926718 | Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. |
| Q33366800 | Intravenous immunoglobulin in neurological disorders: a mechanistic perspective |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q77398105 | Intravenous immunoglobulin inhibits IgE production in human B lymphocytes |
| Q33405903 | Intravenous immunoglobulin therapy: how does IgG modulate the immune system? |
| Q40866049 | Intravenous immunoglobulin treatment of neurological autoimmune diseases |
| Q36757383 | Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. |
| Q37866685 | Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease |
| Q41589724 | Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). |
| Q47915965 | Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein |
| Q34109136 | Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins |
| Q72065827 | Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations |
| Q58393545 | Self-reactive antibodies (natural autoantibodies) in healthy individuals |
| Q41667356 | Use of intravenous immunoglobulin in critically ill patients |
| Q73085297 | [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases] |
| Q80953233 | [Immunomodulatory effects of intravenous immunoglobulins] |
| Q54102494 | [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. |
Search more.